Latest news

Thumbnail image for NICE u-turn approves funding for rare disease therapy Crysvita

NICE u-turn approves funding for rare disease therapy Crysvita

The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita, now endorsing the drug’s use to treat X-linked hypophosphataemia (XLH) in children and young people with growing bones in England and Wales.

5th September 2018

Thumbnail image for FDA rejects Sunovion’s ADHD drug

FDA rejects Sunovion’s ADHD drug

Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators.

3rd September 2018

Thumbnail image for Bayer wins US nod for Jivi

Bayer wins US nod for Jivi

US regulators have approved Bayer’s Jivi (formerly BAY94-9027), a longer-acting Factor VIII therapy designed to reduce the number of infusions necessary to prevent bleeds in patients with Haemophilia A.

31st August 2018

Thumbnail image for Alnylam’s RNA therapy Onpattro bags EU nod

Alnylam’s RNA therapy Onpattro bags EU nod

Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.

31st August 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download